[A pharmacological and clinical review on the activity of a bovine factor VIII derivative obtained by enzymatic hydrolysis].
We report pharmacological, experimental and clinical data of the new drug which decreases bleeding time but is devoid of procoagulant and platelet aggregating properties. The drug, derived from bovine factor VIII by enzymatic hydrolysis, did not show toxicological and immunological effects either in animals or in patients. In addition we report the review of the clinical studies in different pathological situations i.e. ophthalmology, odontostomatology, gynecology etc.